Assessing the impact of economic shocks on the GlaxoSmithKline share price

Assessing the impact of economic shocks on the GlaxoSmithKline share price

Article image

A question on the minds of many investors right now is how economic uncertainty will continue to affect large cap companies, such as GlaxoSmithKline (LON:GSK).

Shares in GlaxoSmithKline are currently trading at 1,764p. But to assess whether the price is likely to fall or rally over the next 12 months, we need an objective way of telling whether it's able to withstand economic shocks. To do that, it's worth looking at the profile of the stock to see where its strengths are.

Importantly, we're interested in finding impartial ways of looking at GlaxoSmithKline – something that takes emotion out of the analysis...

Promisingly, there is evidence that it scores well against some important financial and technical measures. In particular, it shows signs of being a high quality, strong momentum stock.

Research shows that high quality stocks tend to be resilient, cash-generating businesses that can compound investment returns over time. Likewise, strong momentum in price and earnings can be a pointer to positive trends that have the potential to continue.

Here's why these factors matter:

Why quality can pay off

When it comes to stock analysis, company quality tends to be revealed in high profitability and strong industry-leading margins. These kinds of firms are stable, growing and often have accelerating sales and earnings. They also have strong and improving financial histories with no obvious signs of accountancy or bankruptcy risk.

One of the quality metrics for GlaxoSmithKline is its 5-year Return on Capital Employed, which is 13.3%. Long-term, double-digit ROCEs can be a hallmark of companies with the power to grow very profitably.

Harnessing the power of momentum

Positive momentum trends show up in share prices and earnings growth. You can find the clues in stocks that are trading close to their 52 week high prices and outperforming the market. They’ll often be beating broker estimates and getting forecast upgrades and recommendation changes.

There are signs of this at GlaxoSmithKline, where the share price has seen a 27.1% return relative to the market over the past 12 months. Market volatility and economic uncertainty can be a major drag on momentum, but previously strong stocks can be quick to recover when confidence returns.

Overall, a combination of strong quality and momentum can be clues in the search for shares with the potential to deliver solid investment profits over many years. 

In good times, these shares can become expensive to buy. But in volatile markets, there may be chances to buy them at cheaper prices.


Intrigued? 

You should be. The screen that has helped unearth the stock idea detailed in this article is just one of the many tools available at Stockopedia that can help make you a better investor. 

Powered by years of research and huge volumes of data analysis which are normally not available to private investors, we have developed the tools that will give you a better chance of beating the market. 

What are you waiting for. Click here to sign up to your free trial today. 


About us

Stockopedia helps individual investors make confident, profitable choices in the stock market. Our StockRank and factor investing toolbox unlocks institutional-quality insights into thousands of global stocks. Voted “Best Investment Research Tools” and “Best Research Service” at the 2021 UK Investor Magazine awards.

GSK's StockRank™

High FlyerConservative

GSK's StockRank™

With a StockRank of 92, GSK is more attractive than 92% of the 7,586 stocks we cover in Europe, according to our proprietary ranking system.

See the full StockReport

Absolutely Perfect

"Trialed multiple other platforms - this is by far my favourite. Other platforms do not even have half the stuff that you can find on Stockopedia. Love it!"

As per our Terms of Use, Stockopedia is a financial news & data site, discussion forum and content aggregator. Our site should be used for educational & informational purposes only. We do not provide investment advice, recommendations or views as to whether an investment or strategy is suited to the investment needs of a specific individual. You should make your own decisions and seek independent professional advice before doing so. Remember: Shares can go down as well as up. Past performance is not a guide to future performance & investors may not get back the amount invested.